Intralesional and intratumoral therapies in melanoma: current evidence and future perspectives—a narrative review
Background and Objective Immune checkpoint inhibitors and B-Raf proto-oncogene (BRAF)/mitogen-activated protein kinase kinase (MEK)-targeted therapies have transformed the treatment of advanced melanoma, yet treatment resistance and the need for additional locoregional control remain clinical challenges. Intralesional...